The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis

被引：0
|
作者：
Tice, Jeffrey A. [1 ]
Touchette, Daniel R. [2 ]
Lien, Pei-Wen [2 ]
Agboola, Foluso [3 ]
Nikitin, Dmitriy [3 ]
Pearson, Steven D. [3 ]
机构：
[1] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA
[2] Univ Illinois, Coll Pharm, Chicago, IL USA
[3] ICER, Boston, MA USA
来源：
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY | 2022年 / 28卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：119 / 124
页数：6
相关论文
共 50 条
  • [1] A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients
    Pane, Chiara
    Di Stefano, Vincenzo
    Cuomo, Nunzia
    Sarnataro, Alessio
    Vinciguerra, Claudia
    Bevilacqua, Liliana
    Brighina, Filippo
    Rini, Nicasio
    Puorro, Giorgia
    Marsili, Angela
    Garibaldi, Matteo
    Fionda, Laura
    Sacca, Francesco
    JOURNAL OF NEUROLOGY, 2024, 271 (09) : 6209 - 6219
  • [2] A Real-life experience with Eculizumab and Efgartigimod in generalized Myasthenia Gravis patients
    Sacca, F.
    Cuomo, N.
    Russo, C.
    Campanile, M.
    Puorro, G.
    Marsili, A.
    Pane, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 569 - 569
  • [3] Cost-Effectiveness of Eculizumab and Efgartigimod for the Treatment of generalized Myasthenia Gravis (P1-1.Virtual)
    Lien, Pei-Wen
    Agboola, Foluso
    Joshi, Mrinmayee
    Nikitin, Dmitriy
    Yousif, Zaid
    Patel, Shani
    Withanawasam, Vinura
    Jatoi, Saira
    Gebre, Eden
    Tice, Jeffrey
    Campbell, Jonathan
    Touchette, Daniel
    NEUROLOGY, 2022, 98 (18)
  • [4] A real-life experience with Eculizumab and Efgartigimod in generalized myasthenia gravis patients.
    Fionda, L.
    Pane, C.
    Di Stefano, V.
    Cuomo, N.
    Sarnataro, A.
    Vinciguerra, C.
    Bevilacqua, L.
    Brighina, F.
    Rini, N.
    Puorro, G.
    Marsili, A.
    Garibaldi, M.
    Sacca, F.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [5] A Real-life experience with Eculizumab and Efgartigimod in generalized Myasthenia Gravis patients.
    Sacca, F.
    Pane, C.
    Espinosa, P.
    Sormani, M.
    Signori, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 569 - 570
  • [6] Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
    Lien, Pei-Wen
    Joshi, Mrinmayee
    Tice, Jeffrey A.
    Agboola, Foluso
    Nikitin, Dmitriy
    Withanawasam, Vinura
    Jatoi, Saira
    Touchette, Daniel R.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (06): : 517 - 527
  • [7] Eculizumab: A Review in Generalized Myasthenia Gravis
    Dhillon, Sohita
    DRUGS, 2018, 78 (03) : 367 - 376
  • [8] Eculizumab: A Review in Generalized Myasthenia Gravis
    Sohita Dhillon
    Drugs, 2018, 78 : 367 - 376
  • [9] Therapeutic Responses to Efgartigimod for Generalized Myasthenia Gravis in Japan
    Suzuki, Shigeaki
    Uzawa, Akiyuki
    Nagane, Yuriko
    Masuda, Masayuki
    Konno, Shingo
    Kubota, Tomoya
    Samukawa, Makoto
    Ishizuchi, Kei
    Tokuyasu, Daiki
    Handa, Hideo
    Yasuda, Manato
    Kawaguchi, Naoki
    Kimura, Takashi
    Suzuki, Yasushi
    Sugimoto, Takamichi
    Minami, Naoya
    Takahashi, Masanori P.
    Murai, Hiroyuki
    Utsugisawa, Kimiaki
    NEUROLOGY-CLINICAL PRACTICE, 2024, 14 (03)
  • [10] Correction to: Eculizumab: A Review in Generalized Myasthenia Gravis
    Sohita Dhillon
    Drugs, 2018, 78 (5) : 607 - 607
12345